Clinical Trials Logo

Clinical Trial Summary

The purpose of this study is to ascertain whether certain supplements promote excessive urinary oxalate excretion and increase the risk for calcium oxalate kidney stones. Supplements that enhance urinary oxalate excretion, as a result of their oxalate concentration or from some other mechanism (e.g., providing substrate for oxalate biosynthesis) will be identified by the investigators.


Clinical Trial Description

The investigators hypothesize that certain over-the-counter dietary supplements will increase urinary excretion of oxalate as measured in 24-h urine collections. The investigators further hypothesize that the concentration of oxalate in dietary supplements may not be associated with urinary oxalate excretion, suggesting that other nutritional components of the supplements may be exerting an influence over oxalate biosynthesis, oxalate absorption in the gastrointestinal tract, and/or renal oxalate handling. These other factors include the form of oxalate in the supplement (water- vs. non water-soluble) and the supplement's concentration of ascorbic acid. ;


Study Design

Allocation: Randomized, Endpoint Classification: Bio-availability Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Basic Science


Related Conditions & MeSH terms


NCT number NCT02404701
Study type Interventional
Source University of Wisconsin, Madison
Contact
Status Completed
Phase N/A
Start date February 2015
Completion date October 2016

See also
  Status Clinical Trial Phase
Recruiting NCT06138327 - A Study of BMN 255 in Participants With Non-Alcoholic Fatty Liver Disease And Hyperoxaluria Phase 1
Completed NCT02547805 - Evaluate the Effect of ALLN-177 in Reducing Urinary Oxalate in Patients With Secondary Hyperoxaluria and Kidney Stones Over 28 Days Phase 2
Completed NCT02289755 - Evaluating ALLN-177 for Reducing Urinary Oxalate Excretion in Calcium Oxalate Kidney Stone Formers With Hyperoxaluria Phase 2
Completed NCT02038543 - Hydroxyproline Influence on Oxalate Metabolism Phase 1/Phase 2
Completed NCT03095885 - A Pilot Study of Oxalate Absorption in Secondary Hyperoxaluria N/A
Recruiting NCT02780297 - Prospective Research Rare Kidney Stones (ProRKS)
Completed NCT01127087 - Oxazyme in Patients With Hyperoxaluria Phase 1/Phase 2
Not yet recruiting NCT05443932 - Dapagliflozin and Hydrochlorothiazide in Recurring Kidney Stone Patients Phase 4
Completed NCT04756024 - Reference Interval of Spot Urinary Oxalate to Creatinine Ratio in Children
Completed NCT02503345 - Evaluate the Effect of ALLN-177 in Reducing Urinary Oxalate in Patients With Hyperoxaluria and Kidney Stones Phase 2
Completed NCT00199459 - Proteomic Study of Urinary Stone Disease N/A
Completed NCT04119765 - Plasma Oxalate in Patient With Short Bowel
Completed NCT00283387 - Efficacy of Betaine for Reduction of Urine Oxalate in Patients With Type 1 Primary Hyperoxaluria Phase 2
Completed NCT00587041 - Use of Oral Probiotics to Reduce Urinary Oxalate Excretion Phase 1/Phase 2
Completed NCT04571359 - Spot Urine Oxalate to Creatinine Ratio and 24 Hours Urinary Oxalate
Withdrawn NCT00280215 - Renal Protective Effect of ACEI and ARB in Primary Hyperoxaluria Phase 3
Completed NCT00588120 - Enteric Oxalate Absorption Study in Unclassified Hyperoxaluria Phase 1